BAX Expression and Ovarian Cancer Prognosis
Author Information
Author(s): Schuyer M, Burg M E L van der, Henzen-Logmans S C, Fieret J H, Klijn J G M, Look M P, Foekens J A, Stoter G, Berns E M J J
Primary Institution: Department of Medical Oncology (Division of Endocrine Oncology), Department of Pathology, University Hospital Rotterdam/DDHK, The Netherlands
Hypothesis
The study investigates the relationship between the expression of TP53, p21, BAX, and BCL-2 and the prognosis of patients with epithelial ovarian cancer.
Conclusion
BAX expression may serve as a prognostic indicator for ovarian cancer patients, with combined evaluation of BAX and BCL-2 providing additional significance.
Supporting Evidence
- TP53 mutation, p21, and BCL-2 expression were not associated with increased rates of progression and death.
- BAX expression was associated with both progression-free and overall survival.
- Patients expressing both BAX and BCL-2 had longer progression-free and overall survival compared to those without BCL-2 expression.
Takeaway
This study found that a protein called BAX can help predict how well patients with ovarian cancer will do, especially when looked at with another protein called BCL-2.
Methodology
Molecular and immunohistochemical analyses were conducted on ovarian tumor tissues, and associations were evaluated using various statistical methods including Cox proportional hazard model and logistic regression analysis.
Participant Demographics
Patients with epithelial ovarian cancer.
Statistical Information
P-Value
P = 0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website